HYPERHOMOCYSTEINAEMIA IN STROKE - PREVALENCE, CAUSE, AND RELATIONSHIPS TO TYPE OF STROKE AND STROKE RISK-FACTORS

被引:223
作者
BRATTSTROM, L
LINDGREN, A
ISRAELSSON, B
MALINOW, MR
NORRVING, B
UPSON, B
HAMFELT, A
机构
[1] MALMO GEN HOSP,DEPT MED,S-21401 MALMO,SWEDEN
[2] UNIV LUND,S-22101 LUND,SWEDEN
[3] OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006
[4] SUNDSVALL HOSP,DEPT CLIN CHEM,SUNDSVALL,SWEDEN
关键词
CEREBROVASCULAR DISEASE; FOLATE; HOMOCYSTEINE; PYRIDOXAL; 5-PHOSPHATE; RENAL FUNCTION;
D O I
10.1111/j.1365-2362.1992.tb01829.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Moderate hyperhomocysteinaemia is a frequent finding in atherothrombotic cerebrovascular disease. This study confirms and extends this observation. Hyperhomocysteinaemia was present in 57 of 142 survivors with stroke (40%) and in four of 66 controls (6%). Plasma homocysteine concentrations were increased not only in carotid artery disease or lacunar stroke but also in haemorrhagic or embolic strokes. Homocysteine values were unrelated to the presence of hypertension, smoking, or hypercholesterolaemia, or to the concentrations of blood glucose, glycosylated haemoglobin, and plasma fibrinogen. Multiple regression analysis of the patient data showed that about 40% of the variation in plasma homocysteine concentrations could be predicted by the values for the homocysteine metabolism cofactors, blood folate and plasma pyridoxal 5-phosphate and by renal function as reflected in the values for serum creatinine. In patients, urine excretion of homocysteine per unit creatinine was significantly increased and strongly correlated both to the plasma homocysteine concentration and to the values for blood folate, plasma pyridoxal 5-phosphate, and serum vitamin B-12. We conclude that moderate hyperhomocysteinaemia is frequently present in cases of stroke, is independent of other stroke risk factors or the type of stroke, and is partly related to renal function and the concentrations of homocysteine metabolism cofactors.
引用
收藏
页码:214 / 221
页数:8
相关论文
共 38 条
[1]   DETERMINATION OF HOMOCYSTEINE IN PLASMA BY ION-EXCHANGE CHROMATOGRAPHY [J].
ANDERSSON, A ;
BRATTSTROM, L ;
ISAKSSON, A ;
ISRAELSSON, B ;
HULTBERG, B .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1989, 49 (05) :445-449
[2]  
ANDERSSON A, 1991, IN PRESS EUR J CLIN
[3]   PLASMA SULFHYDRYL-CONTAINING AMINO-ACIDS IN PATIENTS WITH CEREBRAL INFARCTION AND IN HYPERTENSIVE SUBJECTS [J].
ARAKI, A ;
SAKO, Y ;
FUKUSHIMA, Y ;
MATSUMOTO, M ;
ASADA, T ;
KITA, T .
ATHEROSCLEROSIS, 1989, 79 (2-3) :139-146
[4]   HETEROZYGOSITY FOR HOMOCYSTINURIA IN PREMATURE PERIPHERAL AND CEREBRAL OCCLUSIVE ARTERIAL-DISEASE [J].
BOERS, GHJ ;
SMALS, AGH ;
TRIJBELS, FJM ;
FOWLER, B ;
BAKKEREN, JAJM ;
SCHOONDERWALDT, HC ;
KLEIJER, WJ ;
KLOPPENBORG, PWC .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (12) :709-715
[5]  
BOERS GHJ, 1985, THESIS U NIJMEGEN
[6]   HIGHER TOTAL PLASMA HOMOCYSTEINE IN VITAMIN-B12 DEFICIENCY THAN IN HETEROZYGOSITY FOR HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY [J].
BRATTSTROM, L ;
ISRAELSSON, B ;
LINDGARDE, F ;
HULTBERG, B .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (02) :175-178
[7]   IMPAIRED HOMOCYSTEINE METABOLISM IN EARLY-ONSET CEREBRAL AND PERIPHERAL OCCLUSIVE ARTERIAL-DISEASE - EFFECTS OF PYRIDOXINE AND FOLIC-ACID TREATMENT [J].
BRATTSTROM, L ;
ISRAELSSON, B ;
NORRVING, B ;
BERGQVIST, D ;
THORNE, J ;
HULTBERG, B ;
HAMFELT, A .
ATHEROSCLEROSIS, 1990, 81 (01) :51-60
[8]   MODERATE HOMOCYSTEINEMIA - A POSSIBLE RISK FACTOR FOR ARTERIOSCLEROTIC CEREBROVASCULAR-DISEASE [J].
BRATTSTROM, LE ;
HARDEBO, JE ;
HULTBERG, BL .
STROKE, 1984, 15 (06) :1012-1016
[9]   FOLIC-ACID - AN INNOCUOUS MEANS TO REDUCE PLASMA HOMOCYSTEINE [J].
BRATTSTROM, LE ;
ISRAELSSON, B ;
JEPPSSON, JO ;
HULTBERG, BL .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1988, 48 (03) :215-221
[10]   FOLIC-ACID RESPONSIVE POSTMENOPAUSAL HOMOCYSTEINEMIA [J].
BRATTSTROM, LE ;
HULTBERG, BL ;
HARDEBO, JE .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1985, 34 (11) :1073-1077